MedPath

Effectiveness of Coping Training for People With HIV Experiencing Treatment Side Effects (The Balance Project)

Not Applicable
Completed
Conditions
HIV Infections
Interventions
Behavioral: Cognitive behavioral coping effectiveness training
Behavioral: Standard care
Behavioral: Single group workshop on coping effectiveness training
Registration Number
NCT00643903
Lead Sponsor
University of California, San Francisco
Brief Summary

This study will evaluate the effectiveness of cognitive behavioral coping training in improving side effect management and treatment adherence in HIV-infected patients who are taking antiretroviral medications.

Detailed Description

HIV is a virus that is transmitted through the exchange of bodily fluids, primarily through sexual intercourse. HIV infections can lead to acquired immunodeficiency syndrome (AIDS), a disease that breaks down the immune system and allows for entry of life-threatening secondary infections. Antiretroviral therapy (ART) has proven to effectively inhibit the replication of HIV and has resulted in a reduction in HIV-related deaths. People infected with HIV who are receiving ART, however, may be confronted with negative physical and emotional side effects. These side effects can impact quality of life (QOL), adherence to medical care, and decisions about health care. Stress and Coping Theory (SCT) is a person-centered approach that considers stressful experiences as person-environment transactions. A cognitive behavioral treatment based upon SCT may help to eliminate or reduce the negative impact of side effects, improve QOL, and maximize benefit from treatment among people living with HIV. This study will evaluate the effectiveness of cognitive behavioral coping training in improving side effect management and treatment adherence in HIV-infected people who are taking ART medications.

This study will involve two phases. Phase 1 will be conducted over 12 months and will include two 1-hour interviews with questions about personal life, family, friends, medications, and medication side effects. After the first interview, participants may be invited to participate in Phase 2, which will last 18 months.

During Phase 2, participants will complete five 2- to 3-hour interviews occurring at baseline and Months 3, 6, 12, and 18. Interviews will include questions about personal life, friends, family, health-related activities, drug-using behaviors, emotions, mental state, and educational background. Participants will be assigned randomly to one of two treatment groups:

* Group 1 participants will receive five individual sessions of cognitive behavioral coping training, beginning after the Month 3 interview. The 90-minute sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.

* Group 2 participants will receive standard care and one group session of coping training, which will be held after the Month 18 interview. The group session will cover the same material that is covered in the individual sessions.

After the last follow-up interview, some participants may also be asked to complete an exit interview about thoughts and feelings on study participation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
250
Inclusion Criteria
  • Confirmed presence of HIV infection
  • Currently receiving ART
  • Experiencing ART side effects
Exclusion Criteria
  • Currently enrolled in another trial
  • Evidence of psychosis or cognitive impairment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2Single group workshop on coping effectiveness trainingParticipants will receive standard care and one delayed group workshop of coping effectiveness training.
1Cognitive behavioral coping effectiveness trainingParticipants will receive five individual sessions of coping effectiveness training.
2Standard careParticipants will receive standard care and one delayed group workshop of coping effectiveness training.
Primary Outcome Measures
NameTimeMethod
Quality of lifeMeasured at Month 18
Secondary Outcome Measures
NameTimeMethod
Medication adherenceMeasured at Month 18

Trial Locations

Locations (1)

University of California, San Francisco

🇺🇸

San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath